Free Trial
NASDAQ:IMA

ImageneBio Q1 2026 Earnings Results & Report

ImageneBio logo
$4.18 -0.06 (-1.39%)
As of 09:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ImageneBio missed analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.95 versus the -$0.70 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

ImageneBio EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.70
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Q1 2026 Earnings FAQ

ImageneBio (NASDAQ:IMA) reported earnings of -$0.95 per share for Q1 2026, missing the consensus estimate of -$0.70. The report was announced on Thursday, May 7, 2026.

ImageneBio Earnings Headlines

My next big call (under $1)
The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.tc pixel
ImageneBio Corporate Event Calendar | NASDAQ:IMA
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA) is a biotechnology company focused on developing molecular diagnostic technologies for precision oncology. The company aims to generate actionable information about cancer biology from blood-based samples, supporting more informed treatment decisions and disease monitoring.

ImageneBio’s platform is designed to analyze tumor-derived molecular signals and may support applications such as cancer detection, treatment selection, and monitoring of treatment response or disease progression. Its work is intended to complement conventional tissue-based testing by providing less-invasive access to tumor information.

The company is headquartered in Israel and serves the global biopharmaceutical and clinical research markets. Publicly available information about its product portfolio, commercial reach, and leadership team remains limited.

View ImageneBio Profile